Del Sol Research Management — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,045	2
2024	Research	$125,785	4
2023	Research	$113,932	11
2022	Research	$22,725	10
2021	Research	$33,070	6
2020	Research	$13,046	3
2019	Research	$9,346	5

Breakdown

Who paid Research payments · program years 2019–2025

Mylan Specialty L.P. $251,691 16 payments
Merck Sharp & Dohme Corporation $28,429 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $19,283 13 payments
Genentech, Inc. $9,436 3 payments
GlaxoSmithKline, LLC. $9,065 3 payments
Moderna TX, Inc. $4,045 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $125,785 4 payments
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $113,932 11 payments
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis $24,538 2 payments
Continuation Study With Budesonide Oral Suspension (Bos) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (Eoe) $18,931 11 payments
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $11,974 1 payment
PH Iib of Mstt1041a in Severe Uncontrolled Asthma $9,436 3 payments
A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $9,065 3 payments
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $4,045 2 payments
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis $3,891 2 payments
Oral Budesonide Suspension (Obs) in Adolescents and Adult Subjects With Eosinophilic Esophagitis: DB, Maintenance $352 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.